2839527-15-8
2839527-15-8
Chemical Structure
Tabirafusp alfa
Synonym(s): OG-2072
- CAS No.: 2839527-15-8
- Formula:N/A
- Molecular Weight:N/A
SMILES: [Tabirafusp alfa]
Biological Activity: Tabirafusp alfa (OG-2072, KSI-101) is a bispecific antibody trap fusion protein that inhibits IL-6 and VEGF. Tabirafusp alfa is a first-in-class, high-strength intravitreal biologic designed to target IL-6 mediated inflammation and VEGF-mediated vascular permeability in macular edema secondary to inflammation (MESI)[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Tabirafusp alfa | 98.08% | Tabirafusp alfa (OG-2072, KSI-101) is a bispecific antibody trap fusion protein that inhibits IL-6 and VEGF. Tabirafusp alfa is a first-in-class, high-strength intravitreal biologic designed to target IL-6 mediated inflammation and VEGF-mediated vascular permeability in macular edema secondary to inflammation (MESI). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Yih-Shiou Hwang, et al. Bispecific trap-antibody inhibiting Interleukin-6 and Vascular Endothelial Growth Factor (KSI-101): Clinical PK/PD cohort in Asian patients with macular edema secondary to inflammation (MESI). ARVO Annual Meeting Abstract. June 2026.
- [2]. John Sinclair, et al. Ocular Toxicity Study of KSI-101 Demonstrates Tolerability after Intravitreal Administration in Cynomolgus Monkeys. ARVO Annual Meeting Abstract. June 2025.
Keywords
